The DEFINE study: a bright future for CETP inhibitors?

Bibliography

• Athyros VG, Kakafika A, Tziomalos K, Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended? Expert Opin Investig Drugs 2008;17:445-9
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Anagnostopoulou KK, Kostakou PM, Mikhailidis DP. Cholesterol ester transfer protein (CETP), postprandial lipemia and hypolipidemic drugs. Curr Med Chem 2009;16:4345-60
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, ; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, van Leuven SI, Burgess L, ; RADIANCE 1 Investigators. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-30
   PubMed Web of Science ®Google Scholar
• Bots ML, Visseren FL, Evans GW, ; RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007;370:153-60
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tardif JC, Nicholls SJ, ; ILLUSTRATE Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-16
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Tuzcu EM, Brennan DM, SA. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 2008;118:2506-14
   PubMed Web of Science ®Google Scholar
• Blasi E, Bamberger M, Knight D, Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure. J Cardiovasc Pharmacol 2009;53:507-16
   PubMed Web of Science ®Google Scholar
• Hu X, Dietz JD, Xia C, Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology 2009;150:2211-19
   PubMed Web of Science ®Google Scholar
• Clark RW, Cunningham D, Cong Y, Assessment of cholesteryl ester transfer protein inhibitors for interaction with proteins involved in the immune response to infection. J Lipid Res 2010;51:967-74
   PubMed Web of Science ®Google Scholar
• Funder JW. Aldosterone, hypertension and heart failure: insights from clinical trials. Hypertens Res 2010;33:872-5
   PubMed Web of Science ®Google Scholar
• Besler C, Heinrich K, Riwanto M, High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease. Curr Pharm Des 2010;16:1480-93
   PubMed Web of Science ®Google Scholar
• Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008;23:370-8
   PubMed Web of Science ®Google Scholar
• Vergeer M, Bots ML, van Leuven SI, Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 2008;118:2515-22
   PubMed Web of Science ®Google Scholar
• Yvan-Charvet L, Matsuura F, Wang N, Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol 2007;27:1132-8
   PubMed Web of Science ®Google Scholar
• Forrest MJ, Bloomfield D, Briscoe RJ, Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 2008;154:1465-73
   PubMed Web of Science ®Google Scholar
• Sofat R, Hingorani AD, Smeeth L, Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Circulation 2010;121:52-62
   PubMed Web of Science ®Google Scholar
• Xie L, Li J, Xie L, Bourne PE. Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS Comput Biol 2009;5:e1000387
   PubMed Web of Science ®Google Scholar
• Vasan RS, Pencina MJ, Robins SJ, Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation 2009;120:2414-20
   PubMed Web of Science ®Google Scholar
• Thompson A, Di Angelantonio E, Sarwar N, Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008;299:2777-88
   PubMed Web of Science ®Google Scholar
• Anagnostopoulou K, Kolovou G, Kostakou P, Pharmacogenetic study of cholesteryl ester transfer protein gene and simvastatin treatment in hypercholesterolaemic subjects. Expert Opin Pharmacother 2007;8:2459-63
   PubMed Web of Science ®Google Scholar
• Briel M, Ferreira-Gonzalez I, You JJ, Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009;338:b92
   PubMed Web of Science ®Google Scholar
• Kakafika A, Athyros VG, Tziomalos K, High density lipoprotein cholesterol and statin trials. Curr Med Chem 2008;15:2265-70
   PubMed Web of Science ®Google Scholar
• Bloomfield D, Carlson GL, Sapre A, Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009;157:352-60. e2
   PubMed Web of Science ®Google Scholar
• Krishna R, Anderson MS, Bergman AJ, Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007;370:1907-14
   PubMed Web of Science ®Google Scholar
• Robinson JG. Dalcetrapib: a review of phase II data. Expert Opin Investig Drugs 2010;19:795-805
   PubMed Web of Science ®Google Scholar
• Kuivenhoven JA, de Grooth GJ, Kawamura H, Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005;95:1085-8
   PubMed Web of Science ®Google Scholar
• Cannon CP, Shah S, Dansky HM, ; the DEFINE Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010. [Epub ahead of print]
   Google Scholar
• Katsiki N, Mikhailidis DP, Athyros VG, Are we getting to lipid targets in real life? Arch Med Sci 2010; In press
   Google Scholar
• Tziomalos K, Athyros VG, Wierzbicki AS, Mikhailidis DP. Lipoprotein a: where are we now? Curr Opin Cardiol 2009;24:351-7
   PubMed Web of Science ®Google Scholar
• Yvan-Charvet L, Kling J, Pagler T, Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol 2010;30:1430-8
   PubMed Web of Science ®Google Scholar